Search Results for "Prasugrel Trial Results Switch"
Original Source: Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.
This study will establish the optimal therapeutic strategy for patients with a coronary artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for treatment/prevention of GI ulceration.
Matching Channels
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
The Asymptomatic Patient With Abnormal Laboratory Test Results
MAP kinase kinase MEK Inhibitors
The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death. The MAPK pathway has emerged as the crucial route between membrane-bound Ras...
Clinical Approvals - news, views, reports and blogs
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and eff...
Cholesteryl Ester Transfer Protein (CETP)
The Cholesteryl Ester Transfer Protein (CETP) facilitates the transfer of cholesterol from HDL to other lipoproteins including LDL, in exchange for triglycerides. The CETP mediated transfer of chole...
Matching News
Who Derives a Significant Benefit From Prasugrel?
Prasugrel sales are flagging as other antiplatelet agents are gaining. Is there a particular population for whom Prasugrel is superior? Journal Watch
TRILOGY ACS: Prasugrel Fails to Beat Clopidogrel
Neutral results for prasugrel vs clopidogrel in medically managed ACS patients mean the newer antiplatelet agent cannot be recommended for use in this patient population, say the TRILOGY ACS researche...
TCT: Hint of Benefit for Prasugrel in Some ACS (CME/CE)
MIAMI (MedPage Today) -- Prasugrel (Effient) may be better than clopidogrel for patients triaged to medical management of acute coronary syndrome using angiography, a subanalysis of the TRILOGY-ACS tr...
Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient (Prasugrel) in Acute ...
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population
Tokyo, Japan (March 14, 2013) — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results from the PRASFIT-Elective study, a double-blind randomized phase 3 trial e...
Prasugrel versus clopidogrel for ACS patients managed without revascularisation
The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel a...
Japan competition for Plavix looms as prasugrel stacks up in comparative trial
New detailed Phase III results for prasugrel show that the Daiichi Sankyo oral antiplatelet agent reduced the risk of major non-fatal cardiovascular events by 23%, with no increase in clinically relev...
Daiichi Sankyo To Apply Prasugrel For PCI-ACS Patients
Daichi Sankyo announced Sept. 21 it “achieved the desired results” in its Phase III trials with the anti-platelet drug prasugrel, and said that it would apply for approval of the drug in Japan in...
Matching PubMed Articles
The aim of this study was to confirm prior modeling data suggesting that prasugrel 5 mg in low-body-weight (LBW) patients would be noninferior to prasugrel 10 mg in higher-body-weight (HBW) patients a...
An algorithm for use of Prasugrel (Effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention at the Brigham and Women's Hospital is presented. Our algorithm, which...
The goal of this study was to assess the offset of the antiplatelet effects of prasugrel and clopidogrel.
Excess of Solid Cancers After Prasugrel: The Food and Drug Administration Outlook.
The TRITON-TIMI 38 was a head-to-head trial to assess the efficacy and safety of the experimental antiplatelet agent prasugrel versus standard care with clopidogrel on top of aspirin. Besides some ear...
